McCarley Robert W
Neuroscience Laboratory, VA Boston Healthcare System, 940 Belmont St., Brockton, MA 02301, USA.
Sleep Med. 2007 Jun;8(4):302-30. doi: 10.1016/j.sleep.2007.03.005. Epub 2007 Apr 30.
This paper presents an overview of the current knowledge of the neurophysiology and cellular pharmacology of sleep mechanisms. It is written from the perspective that recent years have seen a remarkable development of knowledge about sleep mechanisms, due to the capability of current cellular neurophysiological, pharmacological and molecular techniques to provide focused, detailed, and replicable studies that have enriched and informed the knowledge of sleep phenomenology and pathology derived from electroencephalographic (EEG) analysis. This chapter has a cellular and neurophysiological/neuropharmacological focus, with an emphasis on rapid eye movement (REM) sleep mechanisms and non-REM (NREM) sleep phenomena attributable to adenosine. The survey of neuronal and neurotransmitter-related brainstem mechanisms of REM includes monoamines, acetylcholine, the reticular formation, a new emphasis on GABAergic mechanisms and a discussion of the role of orexin/hypcretin in diurnal consolidation of REM sleep. The focus of the NREM sleep discussion is on the basal forebrain and adenosine as a mediator of homeostatic control. Control is through basal forebrain extracellular adenosine accumulation during wakefulness and inhibition of wakefulness-active neurons. Over longer periods of sleep loss, there is a second mechanism of homeostatic control through transcriptional modification. Adenosine acting at the A1 receptor produces an up-regulation of A1 receptors, which increases inhibition for a given level of adenosine, effectively increasing the gain of the sleep homeostat. This second mechanism likely occurs in widespread cortical areas as well as in the basal forebrain. Finally, the results of a new series of experimental paradigms in rodents to measure the neurocognitive effects of sleep loss and sleep interruption (modeling sleep apnea) provide animal model data congruent with those in humans.
本文概述了睡眠机制的神经生理学和细胞药理学的当前知识。本文写作的视角是,由于当前细胞神经生理学、药理学和分子技术能够提供有针对性、详细且可重复的研究,近年来关于睡眠机制的知识有了显著发展,这些研究丰富了源自脑电图(EEG)分析的睡眠现象学和病理学知识并为其提供了信息。本章聚焦于细胞及神经生理学/神经药理学,重点是快速眼动(REM)睡眠机制以及归因于腺苷的非快速眼动(NREM)睡眠现象。对REM睡眠相关的脑干神经元和神经递质机制的综述包括单胺类、乙酰胆碱、网状结构,对GABA能机制的新重点关注以及对食欲素/下丘脑泌素在REM睡眠昼夜巩固中的作用的讨论。NREM睡眠讨论的重点是基底前脑以及作为稳态控制介质的腺苷。控制是通过清醒期间基底前脑细胞外腺苷的积累以及对清醒活跃神经元的抑制来实现的。在长时间睡眠剥夺的情况下,存在通过转录修饰进行稳态控制的第二种机制。作用于A1受体的腺苷会使A1受体上调,这会在给定的腺苷水平下增加抑制作用,有效地增加睡眠稳态调节器的增益。这种第二种机制可能发生在广泛的皮质区域以及基底前脑。最后,在啮齿动物中测量睡眠剥夺和睡眠中断(模拟睡眠呼吸暂停)的神经认知效应的一系列新实验范式的结果提供了与人类数据一致的动物模型数据。